Effect of injections of 6-OHDA into either nucleus accumbens septi or frontal cortex on spontaneous and drug-induced activity.
The effect of injections of 6-hydroxydopamine (6-OHDA) into either frontal cortex (FCx) or nucleus accumbens (NAS) on spontaneous, amphetamine and apomorphine photocell cage activity was studied. Both lesions groups had significant noradrenaline depletion in frontal cortex but only the FCx group had significant dopamine depletion in frontal cortex. Whereas NAS 6-OHDA rats exhibited enhanced apomorphine- and decreased amphetamine-activity there were no differences in activity of the FCx group. 6-OHDA NAS rats also exhibited spontaneous hypoactivity on the third but not the seventh post-operative day; there were no differences in spontaneous activity on either days in the FCx group. In 1975 Kelly, Seviour and Iversen demonstrated that destruction of forebrain dopaminergic terminals induced with injection sof 6-hydroxydopamine (6-OHDA) into the nucleus accumbens septi (NAS) attenuated the locomotor response to 1.5 mg/kg d-amphetamine without affecting stereotypy seen at 5.0 mg/kg. In addition, these rats exhibited an enhanced locomotor response to the dopamine receptor agonist apomorphine, an effect thought to reflect receptor supersensitivity induced by dopamine denervation (Ungerstedt, 1971). Biochemical assay data revealed that dopamine levels were significantly reduced both in nucleus accumbens septi (NAS) and olfactory tubercle (OT) but not neostriatum; thus it was concluded that amphetamine- and apomorphine-induced locomotor activity is mediated by the mesolimbic dopamine system. Since then it has become clear that the A10 group of dopamine (DA) cells bodies in the ventral tegmental area (VTA), give rise to dopamine fibres which innervate not only NAS and OT, but also frontal cortex (Bjorklund and Lindvall, 1978).(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D002395:Catecholamines / Q000378:metabolism; D002540:Cerebral Cortex; D006801:Humans; D006892:Hydroxydopamines / Q000008:administration & dosage / Q000494:pharmacology*; D007267:Injections; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009714:Nucleus Accumbens; D016627:Oxidopamine; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects; D013997:Time Factors
D002395:Catecholamines; D006892:Hydroxydopamines; D016627:Oxidopamine